# Sichuan Kelun-Biotech Source: https://onco.cc/companies/kelun-biotech/ OnCo record `kelun-biotech` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence. ## TL;DR Chinese ADC developer whose TROP2 ADC sac-TMT was licensed to Merck in one of the largest China-out deals. ## Summary Sichuan Kelun-Biotech, based in Chengdu and listed in Hong Kong as 6990.HK, is the Chinese antibody-drug conjugate developer whose TROP2 ADC sacituzumab tirumotecan, or sac-TMT, was licensed to Merck in one of the largest China-out deals, worth up to 9.3 billion dollars. Sac-TMT was the first TROP2 ADC approved in China, MK-3120 is its Nectin-4 ADC, and a broad ADC platform sits behind the Merck partnership, with Binghe Xu among the investigators linked. OnCo connects it to triple-negative breast cancer, to the TROP2 ADC roadmap that runs from sacituzumab govitecan through datopotamab deruxtecan to sac-TMT, to Sichuan Cancer Hospital and to the NMPA. Whether sac-TMT can repeat its Chinese results in Western trials is the open question. Sacituzumab tirumotecan has its own page. ## Fields - Kind: Company - Last checked: 2026-09-04 - HQ: Chengdu - Type: biotech - Website: https://www.kelun-biotech.com - Ticker: 6990.HK ## Sources - Official website: https://www.kelun-biotech.com ## Connected records - fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/) - drugs: [A166](https://onco.cc/drugs/a166/), [KL-A167](https://onco.cc/drugs/kl-a167/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/), [SKB105](https://onco.cc/drugs/skb105/) - trials: [A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastati](https://onco.cc/trials/nct07814066/), [A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities](https://onco.cc/trials/nct07308106/), [A Phase II Study of SKB571 in Patients With Lung Cancer](https://onco.cc/trials/nct07230405/), [A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients](https://onco.cc/trials/nct05870319/), [A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer](https://onco.cc/trials/nct07299825/), [A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy](https://onco.cc/trials/nct06968585/), [A Study of KL590586 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05265091/), [A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-](https://onco.cc/trials/nct05816252/), [A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan](https://onco.cc/trials/nct06670196/), [A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P](https://onco.cc/trials/nct06711900/), [A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06448312/), [A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer](https://onco.cc/trials/nct06279364/), [A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy](https://onco.cc/trials/nct07071337/), [A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors](https://onco.cc/trials/nct07448922/), [A Study of SKB518 in Patients With Lung Cancer](https://onco.cc/trials/nct07019675/), [A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07622186/), [KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma](https://onco.cc/trials/nct05294172/), [Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)](https://onco.cc/trials/nct04152499/), [Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto](https://onco.cc/trials/nct07329322/), [Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)](https://onco.cc/trials/nct07501169/), [Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma](https://onco.cc/trials/nct07324629/), [Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases](https://onco.cc/trials/nct07343479/), [SKB103 for Injection in Advanced Solid Tumors](https://onco.cc/trials/nct07459998/), [SKB105 for Injection in Advanced Solid Tumors](https://onco.cc/trials/nct07380386/), [SKB118 Injection in Advanced Solid Tumors](https://onco.cc/trials/nct07586943/), [SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.](https://onco.cc/trials/nct05351788/), [SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors](https://onco.cc/trials/nct05642780/), [SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07697586/), [SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer](https://onco.cc/trials/nct05347134/), [SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct05631262/), [SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma](https://onco.cc/trials/nct07700667/), [SKB500 Combinations in Patients With Small Cell Lung Cancer](https://onco.cc/trials/nct07296809/), [SKB565 for Injection in Advanced Solid Tumors](https://onco.cc/trials/nct07545265/), [Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer](https://onco.cc/trials/nct06081959/), [Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC](https://onco.cc/trials/nct07341100/), [Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC](https://onco.cc/trials/nct07819578/) - cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/) - roadmaps: [TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET](https://onco.cc/roadmaps/trop2-adc-roadmap/) - people: [Binghe Xu](https://onco.cc/people/xu-binghe/) - institutions: [National Medical Products Administration / Center for Drug Evaluation](https://onco.cc/institutions/nmpa-cde/), [Sichuan Cancer Hospital](https://onco.cc/institutions/sichuan-cancer-hospital/) --- JSON: https://onco.cc/api/v1/entities/kelun-biotech.json